Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brendan Smyth

Showing results (11-20 of 64) with videos related to

Pageof 7
Sort By:
Nephrology (Carlton, Vic.)|September 30, 2018
Dialysis catheter management practices in Australia and New ZealandBrendan Smyth, Sradha Kotwal, Martin Gallagher, et al.
Kidney International Supplements|March 10, 2020
Dialysis funding, eligibility, procurement, and protocols in low- and middle-income settings: results from the International Society of Nephrology collection surveyValerie A Luyckx, Brendan Smyth, David C H Harris, et al.
The Journal of Vascular Access|May 31, 2019
Arteriovenous access practices in Australian and New Zealand dialysis unitsBrendan Smyth, Sradha Kotwal, Martin Gallagher, et al.
Clinical Journal of the American Society of Nephrology : CJASN|January 6, 2022
Cannabinoids for Symptom Management in Patients with Kidney Failure: A Narrative ReviewHayley Worth, Daniel V O'Hara, Neeru Agarwal, et al.
Canadian Journal of Kidney Health and Disease|December 29, 2022
Findings of Sodium-Glucose Cotransporter-2 Inhibitor Kidney Outcome Trials Applied to a Canadian Chronic Kidney Disease Population: A Retrospective Cohort StudyTae Won Yi, Mohammad Atiquzzaman, Yuyan Zheng, et al.
Clinical Kidney Journal|June 6, 2022
Trimming the fat: is there a health economic case for the use of new lipid-lowering drugs in chronic kidney disease? A scoping reviewAlexandra Gallagher, Blaise Agresta, Brendan Smyth, et al.
JAMA Internal Medicine|July 9, 2019
Representativeness of Randomized Clinical Trial Cohorts in End-stage Kidney Disease: A Meta-analysisBrendan Smyth, Anna Haber, Konlawij Trongtrakul, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|February 2, 2024
Estimating a Minimal Important Difference for the EQ-5D-5L Utility Index in Dialysis PatientsAmanda N Siriwardana, Anna T Hoffman, Rachael L Morton, et al.
Clinical Kidney Journal|October 24, 2025
Increased risk of cardiac death with cumulative exposure to fluid overload and dialysate sodium ≤138 mmol/l in hemodialysis patientsMartin Christa, Brendan Smyth, Kaitlin J Mayne, et al.
Canadian Journal of Kidney Health and Disease|January 1, 2024
Identifying Barriers and Facilitators for Increasing Uptake of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors in British Columbia, Canada, using the Consolidated Framework for Implementation ResearchTae Won Yi, Daniel V O'Hara, Brendan Smyth, et al.
Pageof 7

Showing results (11-20 of 64) with videos related to

Sort By:
Pageof 7
Nephrology (Carlton, Vic.)|September 30, 2018
Dialysis catheter management practices in Australia and New ZealandBrendan Smyth, Sradha Kotwal, Martin Gallagher, et al.
Kidney International Supplements|March 10, 2020
Dialysis funding, eligibility, procurement, and protocols in low- and middle-income settings: results from the International Society of Nephrology collection surveyValerie A Luyckx, Brendan Smyth, David C H Harris, et al.
The Journal of Vascular Access|May 31, 2019
Arteriovenous access practices in Australian and New Zealand dialysis unitsBrendan Smyth, Sradha Kotwal, Martin Gallagher, et al.
Clinical Journal of the American Society of Nephrology : CJASN|January 6, 2022
Cannabinoids for Symptom Management in Patients with Kidney Failure: A Narrative ReviewHayley Worth, Daniel V O'Hara, Neeru Agarwal, et al.
Canadian Journal of Kidney Health and Disease|December 29, 2022
Findings of Sodium-Glucose Cotransporter-2 Inhibitor Kidney Outcome Trials Applied to a Canadian Chronic Kidney Disease Population: A Retrospective Cohort StudyTae Won Yi, Mohammad Atiquzzaman, Yuyan Zheng, et al.
Clinical Kidney Journal|June 6, 2022
Trimming the fat: is there a health economic case for the use of new lipid-lowering drugs in chronic kidney disease? A scoping reviewAlexandra Gallagher, Blaise Agresta, Brendan Smyth, et al.
JAMA Internal Medicine|July 9, 2019
Representativeness of Randomized Clinical Trial Cohorts in End-stage Kidney Disease: A Meta-analysisBrendan Smyth, Anna Haber, Konlawij Trongtrakul, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|February 2, 2024
Estimating a Minimal Important Difference for the EQ-5D-5L Utility Index in Dialysis PatientsAmanda N Siriwardana, Anna T Hoffman, Rachael L Morton, et al.
Clinical Kidney Journal|October 24, 2025
Increased risk of cardiac death with cumulative exposure to fluid overload and dialysate sodium ≤138 mmol/l in hemodialysis patientsMartin Christa, Brendan Smyth, Kaitlin J Mayne, et al.
Canadian Journal of Kidney Health and Disease|January 1, 2024
Identifying Barriers and Facilitators for Increasing Uptake of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors in British Columbia, Canada, using the Consolidated Framework for Implementation ResearchTae Won Yi, Daniel V O'Hara, Brendan Smyth, et al.
Pageof 7